Cargando…

c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation

SIMPLE SUMMARY: Natural killer group 2, member D ligand (NKG2DL) is the most relevant ligand of NK cells to perform immune surveillance and is rarely expressed in most small cell lung cancer (SCLC) with the unclear mechanism. This study aimed to investigate the mechanisms underlying the NKG2DL defic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Peiyan, Sun, Xiaodan, Li, Hui, Liu, Yan, Cui, Yanan, Tian, Lin, Cheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833590/
https://www.ncbi.nlm.nih.gov/pubmed/35158730
http://dx.doi.org/10.3390/cancers14030457
_version_ 1784648981154889728
author Zhao, Peiyan
Sun, Xiaodan
Li, Hui
Liu, Yan
Cui, Yanan
Tian, Lin
Cheng, Ying
author_facet Zhao, Peiyan
Sun, Xiaodan
Li, Hui
Liu, Yan
Cui, Yanan
Tian, Lin
Cheng, Ying
author_sort Zhao, Peiyan
collection PubMed
description SIMPLE SUMMARY: Natural killer group 2, member D ligand (NKG2DL) is the most relevant ligand of NK cells to perform immune surveillance and is rarely expressed in most small cell lung cancer (SCLC) with the unclear mechanism. This study aimed to investigate the mechanisms underlying the NKG2DL deficiency in C-MYC (MYC)-amplificated N-type SCLC (SCLC-N) with less immune infiltrate. Our data showed that c-Myc was the suppressor of NKG2DL in SCLC-N. Further, c-Myc suppressed the transcription of NKG2DL by recruiting HDAC3 to deacetylate H3K9ac at the promoter of MICA and MICB in SCLC-N and inhibited the cytotoxicity of NK cells. The above findings revealed the role of c-Myc/HDAC3 axis in the regulation of NKG2DL expression, supplying a new perception for comprehending the mechanism of SCLC-N immune escape, which was poorly understood and providing the therapeutic targets that SCLC-N may benefit from. ABSTRACT: SCLC is an aggressive malignancy with a very poor prognosis and limited effective therapeutic options. Despite the high tumor mutational burden, responses to immunotherapy are rare in SCLC patients, which may be due to the lack of immune surveillance. Here, we aimed to examine the role and mechanism of oncogene MYC in the regulation of NKG2DL, the most relevant NK-activating ligand in SCLC-N. Western Blotting, Immunofluorescence, flow cytometry, quantitative real-time PCR (qRT-PCR), Co-Immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Cytotoxicity assay were used on H2227 cells, H446 cells, and other SCLC cell lines, and we found that c-Myc negatively regulated NKG2DL expression in SCLC-N cells. Mechanistically, c-Myc recruited HDAC3 to deacetylate H3K9ac at the promoter regions of MICA and MICB, suppressing the MICA/B expression of SCLC-N cells and the cytotoxicity of NK cells. Treatment with selective HDAC3 inhibitor up-regulated the expression of NKG2DL on SCLC-N cells and increased the cytotoxicity of NK cells. Furthermore, analysis of the CCLE and Kaplan-Meier plotter data performed the negative correlation between MYC and NKG2DL in SCLC-N cells and the correlation with the prognosis of lung cancer patients. Collectively, the results provided the new insight into the role and mechanism of c-Myc/HDAC3 axis in NKG2DL expression and innate immune escape of SCLC-N, suggesting the potential target for SCLC-N immunotherapy.
format Online
Article
Text
id pubmed-8833590
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88335902022-02-12 c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation Zhao, Peiyan Sun, Xiaodan Li, Hui Liu, Yan Cui, Yanan Tian, Lin Cheng, Ying Cancers (Basel) Article SIMPLE SUMMARY: Natural killer group 2, member D ligand (NKG2DL) is the most relevant ligand of NK cells to perform immune surveillance and is rarely expressed in most small cell lung cancer (SCLC) with the unclear mechanism. This study aimed to investigate the mechanisms underlying the NKG2DL deficiency in C-MYC (MYC)-amplificated N-type SCLC (SCLC-N) with less immune infiltrate. Our data showed that c-Myc was the suppressor of NKG2DL in SCLC-N. Further, c-Myc suppressed the transcription of NKG2DL by recruiting HDAC3 to deacetylate H3K9ac at the promoter of MICA and MICB in SCLC-N and inhibited the cytotoxicity of NK cells. The above findings revealed the role of c-Myc/HDAC3 axis in the regulation of NKG2DL expression, supplying a new perception for comprehending the mechanism of SCLC-N immune escape, which was poorly understood and providing the therapeutic targets that SCLC-N may benefit from. ABSTRACT: SCLC is an aggressive malignancy with a very poor prognosis and limited effective therapeutic options. Despite the high tumor mutational burden, responses to immunotherapy are rare in SCLC patients, which may be due to the lack of immune surveillance. Here, we aimed to examine the role and mechanism of oncogene MYC in the regulation of NKG2DL, the most relevant NK-activating ligand in SCLC-N. Western Blotting, Immunofluorescence, flow cytometry, quantitative real-time PCR (qRT-PCR), Co-Immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Cytotoxicity assay were used on H2227 cells, H446 cells, and other SCLC cell lines, and we found that c-Myc negatively regulated NKG2DL expression in SCLC-N cells. Mechanistically, c-Myc recruited HDAC3 to deacetylate H3K9ac at the promoter regions of MICA and MICB, suppressing the MICA/B expression of SCLC-N cells and the cytotoxicity of NK cells. Treatment with selective HDAC3 inhibitor up-regulated the expression of NKG2DL on SCLC-N cells and increased the cytotoxicity of NK cells. Furthermore, analysis of the CCLE and Kaplan-Meier plotter data performed the negative correlation between MYC and NKG2DL in SCLC-N cells and the correlation with the prognosis of lung cancer patients. Collectively, the results provided the new insight into the role and mechanism of c-Myc/HDAC3 axis in NKG2DL expression and innate immune escape of SCLC-N, suggesting the potential target for SCLC-N immunotherapy. MDPI 2022-01-18 /pmc/articles/PMC8833590/ /pubmed/35158730 http://dx.doi.org/10.3390/cancers14030457 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhao, Peiyan
Sun, Xiaodan
Li, Hui
Liu, Yan
Cui, Yanan
Tian, Lin
Cheng, Ying
c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title_full c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title_fullStr c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title_full_unstemmed c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title_short c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
title_sort c-myc targets hdac3 to suppress nkg2dl expression and innate immune response in n-type sclc through histone deacetylation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833590/
https://www.ncbi.nlm.nih.gov/pubmed/35158730
http://dx.doi.org/10.3390/cancers14030457
work_keys_str_mv AT zhaopeiyan cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT sunxiaodan cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT lihui cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT liuyan cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT cuiyanan cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT tianlin cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation
AT chengying cmyctargetshdac3tosuppressnkg2dlexpressionandinnateimmuneresponseinntypesclcthroughhistonedeacetylation